Wednesday, May 18, 2022 | The Latest Research, Commentary, And News From Health Affairs
Dear John, Don't miss out on our health reform–focused newsletter written by Katie Keith. The newsletter examines health policy developments—from legislation to litigation—and explains what these changes mean for patients, payers, providers, and other key health care stakeholders.
In the article, the authors pay particular attention to the ten drugs approved despite
a negative advisory committee vote.
They find that the number of new approved drugs receiving advisory committee review decreased from 59 percent in 2011 to only 6 percent in 2021.
The authors also note inconsistencies in the wording of FDA questions posed to the advisory committees. Daval and authors propose that the FDA provide clear and specific criteria for how it chooses to subject new drugs to external scrutiny.
Health Affairs is the leading peer-reviewedjournalat the intersection of health, health care, and policy. Published monthly by Project HOPE, the journal is available in print and online. Late-breaking
content is also found through healthaffairs.org, Health Affairs Today, and Health Affairs Sunday Update.
Project HOPE is a global health and humanitarian relief organization that places power in the hands of local health care workers to save lives across the globe. Project HOPE has published Health Affairs since 1981.
